RYAN SCHIPPER: Open Payments
NPI 1356065932 · GRAND RAPIDS, MI. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,910 in 75 payments from 22 companies in 2025. Trend: 2023 $644 · 2024 $613 · 2025 $1,910
Food & beverage: $1,910
| Company | Payments | Amount |
|---|---|---|
| GENZYME CORPORATION | 9 | $382 |
| Novartis Pharmaceuticals Corporation | 25 | $297 |
| Bard Peripheral Vascular, Inc. | 4 | $241 |
| Merck Sharp & Dohme LLC | 6 | $155 |
| AstraZeneca Pharmaceuticals LP | 3 | $154 |
| Agios Pharmaceuticals, Inc. | 3 | $85 |
| GlaxoSmithKline, LLC. | 4 | $76 |
| Geron Corporation | 2 | $72 |
| ABBVIE INC. | 3 | $67 |
| Incyte Corporation | 2 | $48 |
Products named: WAYRILZ, Trek, KEYTRUDA, CALQUENCE, KISQALI, SCEMBLIX, PYRUKYND, SARCLISA.
Industry payments across MI — which companies pay providers there.
